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Abstract
Background: Cognitive behavioral therapy (CBT) represents a learning process leading to symptom relief and
resulting in long-term changes in behavior. CBT for panic disorder is based on exposure and exposure-based
processes can be studied in the laboratory as extinction of experimentally acquired fear responses. We have
recently demonstrated that the ability to extinguish learned fear responses is associated with a functional genetic
polymorphism (COMTval158met) in the COMT gene and this study was aimed at transferring the experimental
results on the COMTval158met polymorphism on extinction into a clinical setting.
Methods: We tested a possible effect of the COMTval158met polymorphism on the efficacy of CBT, in particular
exposure-based treatment modules, in a sample of 69 panic disorder patients.
Results: We present evidence that panic patients with the COMTval158met met/met genotype may profit less
from (exposure-based) CBT treatment methods as compared to patients carrying at least one val-allele. No
association was found with the 5-HTTLPR/rs25531 genotypes which is presented as additional material.
Conclusions: We were thus able to transfer findings on the effect of the COMTval158met polymorphism from an
experimental extinction study obtained using healthy subjects to a clinical setting. Furthermore patients carrying a
COMT val-allele tend to report more anxiety and more depression symptoms as compared to those with the met/
met genotype. Limitations of the study as well as possible clinical implications are discussed.
Trial registration: Clinical Trial Registry name: Internet-Versus Group-Administered Cognitive Behavior Therapy for
Panic Disorder (IP2). Registration Identification number: NCT00845260, http://www.clinicaltrials.gov/ct2/show/
NCT00845260
Background
Cognitive behavioral therapy (CBT) represents a learn-
ing process leading to symptom relief. It results in long-
term changes in behavior, which have their correlates in
altered neural activity [for a review see e.g., [1]], gene
expression as well as synaptic connectivity in the brain
[2]. CBT for anxiety disorders generally, and panic dis-
order (PD) specifically, is based on exposure. These
exposure-based processes can be studied in the labora-
tory as the extinction of experimentally acquired fear
responses. We have recently reported that the ability to
extinguish learned fear responses is associated with a
functional polymorphism (COMTval158met) in the
Catechol-O-methyltransferase (COMT) gene [3].
COMT is a methylation enzyme metabolizing monoa-
minergic neurotransmitters including dopamine [4]. The
COMTval158met polymorphism is an A/G single-
nucleotide polymorphism (SNP) causing an amino acid
exchange from valine (val) to methionine (met) at
codon 158. The val-allele is associated with a three- to
four-fold higher COMT activity as compared to the
thermolabile met-allele [5,6].
The met/met genotype has been associated with resis-
tance to extinction [3] and higher severity of PTSD even
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has been associated with negative emotionality, altered
prefrontal cortex activity [for a review see e.g. [8]] and
has been suggested to be associated with reduced cogni-
tive flexibility but increased cognitive stability [9]. Given
the cognitive change induced by therapy and the pivotal
role of prefrontal brain areas in extinction, the met-
allele might also be associated with the efficacy of CBT
in PD.
The val-allele of the COMTval158met polymorphism
has been associated with PD in several case-control stu-
dies [e.g., [10,11]] and a recent meta-analysis supports
an association of the COMT val-allele with the diagnosis
of PD in Caucasians [12], despite of contradictory
findings.
This study aimed at transfering the experimental
results of the COMTval158met polymorphism on
extinction into a clinical setting by investigating the effi-
cacy of CBT (in particular exposure-based treatment
modules) in a sample of PD patients, genotyped for the
COMTval158met.
Methods
Patient population
Patients were recruited from a randomized clinical
equivalence trial (CET) of regular cognitive-behavioral
group therapy (gCBT) vs. internet-based CBT (iCBT)
f o rP D[ 1 3 ] ( s e ea d d i t i o n a lf i l e1 ) .A tt h et i m eo fi n c l u -
sion to the CET, patients that consented also to partici-
pate in clinical genetic studies donated a blood sample.
Inclusion criteria were: (1) fulfilling DSM-IV criteria for
PD with/without agoraphobia (PD/A), (2) PD/A primary
diagnosis, (3) non-physiological etiology of panic symp-
toms, (4) age at least 18 years, (5) not suffering from
severe depression or suicidal ideation, (6) if taking pre-
scribed drugs for panic disorder, having had a constant
dosage for 2 months prior to inclusion (7) not under-
going other CBT or psychotherapy.
Eighty-seven patients consented to participate in the
study. Fourteen patients were excluded because of
excessive missing data (e.g drop-out right after inclusion
before beginning CBT), three patients were excluded
because of questionable clinical significance of their PD
at the time of inclusion, and one patient was excluded
due to non-Caucasian ancestry. This left us with a final
sample of 69 Caucasian patients (see Additional file 1
Figure S1), with 26 male (mean = 32.8 years, SD = 7.6,
range 22-53) and 43 female (mean = 36.9 years, SD =
10.3, range 23-61) patients. The majority (n = 39) of the
patients were referred from primary health care, 25 by
self-referral and five by psychiatric outpatient care units.
Thirty patients were pharmacologically treated (SSRIs,
other antidepressants, Benzodiazepine) at assignment to
the study, with a stable dosage for at least 2 months.
Hence, symptoms were still present in this group in
spite of medication. Patients were allowed to continue
pharmacological treatment during CBT. All patients
provided written informed consent and the study was
approved by the Regional Ethics Committee in Stock-
holm and was carried out in accordance with the
Declaration of Helsinki.
Diagnostic procedure
A psychiatrist or a supervised resident in psychiatry per-
formed an in-person structured clinical interview includ-
ing the Mini-International Neuropsychiatric Interview
(M.I.N.I. [14]). The diagnostic procedures were per-
formed blind to genotype and group assignment (gCBT
vs ICBT) in the treatment trial.
After each of the ten modules of CBT treatment,
patients filled in the Hospital Anxiety and Depression
Scale [HADS, [15]] which comprises an anxiety subscale
(7 items) and a depression subscale (7 items). All items
are rated on a 4-point likert scale. Overall, the subscales
have good psychometric properties [16]. We used the
HADS as it measures symptoms of anxiety and depres-
sion in a discrete way without much effort needed from
the patient.
Treatment
Patients were randomly assigned to one of two treat-
ment arms: regular group CBT (gCBT, N = 38) or inter-
net-based CBT (ICBT, N = 31). Both treatments lasted
for ten weeks and the content was similar, with the
exception of the format. The treatment program con-
sisted of ten modules (M), all are based on well estab-
lished CBT-principles: psycho-education (M1), cognitive
restructuring (M2-M3), interoceptive exposure (M4-
M5), in vivo exposure (for agoraphobic situations, M6-
M9) and relapse prevention (M10). In the ICBT arm, a
text-based manual [17] was administered via a web-page
with support via e-mail. In the gCBT arm, the manual
was administered in print-out form, as well as presented
by 2 psychologists. The 10 modules consisted of text as
well as exercises, to be performed in the patient’s every-
day life. In the ICBT arm, access to the next module
was not provided before the psychologist had received
the answers sent by way of the interactive forms. A psy-
chologist read and answered the communication manu-
ally. In the gCBT arm, the group met with the two
psychologists during weekly two-hour sessions. Both
treatment groups (gCBT vs. ICBT) did not differ in
their treatment outcome [13].
Genotyping
DNA was extracted from whole blood [18] and genotyping
for COMTval158met was performed as described in detail
earlier [3]. Briefly, we used the Taqman® allelic
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an ABI HT7900 (Applied Biosystems, Foster City, CA).
Table 1 displays the distribution of variables of inter-
est between the different genotype groups (val-carriers
[val/val and val/met] vs. met/met).
Additional genotyping procedures (for 5-HTTLPR/
rs25531) are described as additional methods (see addi-
tional file 2) accompanying additional analyses and
results (see additional file 3) discussed in the discussion
section.
Statistical analysis
Statistical analysis were performed using SPSS for Win-
dows v15 (SPSS Inc., Chicago, IL, USA) and graphs
were made using Origin®8 (OriginLab®, Northampton,
MA, USA). Val-carriers (val/val + val/met) were merged
to a val-carrier group ap r i o r i[3]. However, for means
of completeness and in order to facilitate comparability
between different studies, we also report results from
analyses comparing all three COMTval158met geno-
types (val/val, val/met, met/met) as additional material
(see additional file 4) as well as results based on the bi-
and triallelic 5-HTTLPR (see additional files 2 and 3).
Normal distribution of variables was tested using Sha-
piro-Wilk’s test. Non-parametric tests were used when
data significantly differed from the normal distribution
(which was the case for the HADS post-treatment anxi-
ety and the depression subscale and all difference scores
except for the one mentioned above), otherwise para-
metric tests were applied (in case of the HADS pre-
treatment anxiety and the depression scale and the cog-
nitive block-exposure block difference score for the
HADS depression scale, see above for details).
Due to a considerable amount of missing HADS mea-
surements after each module (in particular after M8 and
M9), we were unable to perform repeated measures
ANOVAs for the 9 measurements during treatment as
SPSS excludes cases list-wise.
Thus we combined modules with a similar content to
blocks of modules and calculated the mean HADS score
of the Modules included in each block. The mean
HADS ratings after Module M1-M3 formed a cognitive
block and the mean HADS scores for Module M4-M9
were grouped into an exposure block. This was done for
both the anxiety and depression subscale.
As we were particularly interested in a differential
response to exposure-based modules, we calculated dif-
ference scores between the cognitive and the exposure
block [mean cognitive-block - mean exposure-block] as
well as differences between the pre-treatment HADS
rating and the cognitive block [mean pretreatment -
mean cognitive-block]. Difference scores were compared
between genotype groups by ANOVAS with difference
score as the dependent and COMTval158met genotype
as the independent variable.
Partial Eta
2 is reported as measurements of effect size.
We report results corrected for multiple comparisons by
the Bonferroni correction. HWE was tested using the
Pearson’s goodness-of-fit c
2 (df = 1) provided on a web-
site by http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/
hwa1.pl.
Results
Patient characteristics and genotype frequencies
COMT genotype frequencies differed significantly from
HWE (N = 18 val/val, N = 22 val/met, N = 25 met/
met), Pearson’s goodness-of fit chi-Square (df = 1), chi2
= 8.25, p < 0.01. The genotype groups (val-carriers [val/
val and val/met] vs. met/met) did not differ significantly
from each other in any descriptive or clinical variable
except for frequency of comorbidity with mild major
depressive episode (see Table 1). Patients with the
COMT met/met genotype had a lower incidence of
comorbidity with depression as compared to val-carriers.
We have not included this variable as a covariate in our
analyses as this would be questionable in the light of
Table 1 Descriptives for COMTval158met genotype groups
COMTval158met Val/val and val/met Met/met X
2 p-value
a Mann-Whitney U-test
p-value
N4 0 2 9
sex (M/F) 15/25 11/18 0.97 -
mean age (SD) 37.3 (10.9) 32.7 (6.6) - 0.11
age of onset (SEM) 27.9 (10.7) 25.3 (8.6) - 0.39
duration of illness (SEM) 9.8 (11.9) 7.2 (6.4) - 0.80
Depresssion (yes/no) 9/31 1/28 0.03* -
iCBT/gCBT 14/26 17/12 0.052 -
Number of modules 6.93 (2.1) 6.31 (2.8) 0.30
Co-medication
b (yes/no) 16/24 14/15 0.50
a: chi2 (df = 1)
b: any medication (including SSRI, Benzodiazepine, tricyclic antidepressants)
iCBT: internet-based CBT; gCBT: group CBT
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(see limitations section in the discussion). Still, when
depression was included as a covariate in our primary
analyses, results did not change substantially (see
below).
Importantly, the number of patients using psychophar-
maceuticals in addition to CBT treatment did not differ
between the two COMT val158met genotype groups
(Table 1) or between the two treatment arms, x
2 (df =
1) = 0.055, p = 0.82. The female:male ratio did not differ
between the genotype groups (see Table 1) nor between
the two treatment arms, x
2 (df = 1) = 0.12, p = 0.73.
Thus, it was considered unnecessary to include these
variables (co-medication and sex) as covariates.
Symptomatic profile prior to CBT treatment
Univariate ANOVASs with genotype as the independent
and mean HADS pre-treatment scores (separate for the
two subscales) as the dependent variables revealed, that
patients carrying at least one COMT158val allele
reported tendentially more symptoms as compared to
patients with the met/met genotype in the anxiety sub-
scale of the HADS, F(1,66) = 3.73, p = 0.058, ph
2 =0 . 0 5 ,
and significantly more symptoms in the depression sub-
scale of the HADS F(1,66) = 6.33, p = 0.014, ph
2 = 0.09.
Symptomatic profile after treatment
Mann-Whitney U-tests with genotype as the group vari-
able and mean HADS post-treatment scores (separate
for the two subscales) as the test variables revealed, no
significant differences between the COMTval158met
genotype groups on the HADS anxiety scale, p = 0.46.
However, patients with the val-allele reported signifi-
cantly more symptoms on the depression subscale, p =
0.04, even after treatment.
Symptom relief during the course of treatment
Difference score pre-treatment - cognitive block
An univariate ANOVA with the difference score
between the mean HADS anxiety score prior to treat-
ment and during the cognitive block as the dependent
and COMT158met genotype as the independent variable
Figure 1 Difference scores between the HADS anxiety mean scores pre-treatment and during the cognitive block as well as during
the cognitive vs. the exposure block for COMT 158val-carriers (black bars) and patients with the met/met genotype (white bars).
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type on this difference score, F(1,62) < 1. No effect was
found for the HADS depression scale during the course
of treatment using the same analysis as described above
either, F(1,62) < 1.1.
Difference score cognitive block - exposure block
A univariate ANOVA with the difference score between
the mean HADS anxiety score of the cognitive and the
m e a nH A D Sa n x i e t ys c o r eo ft h ee x p o s eb l o c ka st h e
dependent, COMT158met genotype (met/met vs. val-
carriers) as the independent variable revealed a signifi-
cant effect of COMTval158met genotype, F(1,58) = 5.40,
p = 0.024, ph
2 = 0.09. Patients with the met/met geno-
type showed significantly less symptom relief during the
exposure block as compared to COMT 158val-carriers
(see Figure 1).
An additional analysis including medication status
( y e s / n o ) ,a g e ,s e x ,p r e - t r e a t m e n tH A D Sa n x i e t ys c o r e
and the type of treatment (ICBT vs. gCBT) and comor-
bidity with depression as covariates in the analysis on
the difference score between the cognitive and the expo-
sure block revealed no significant impact of these vari-
ables. Importantly, the effect of COMTval158met
genotype on the outcome measure still remained statis-
tically significant when controlling for all these variables,
F(1,52) = 4.73, p = 0.034, ph
2 = 0.08.
However, sex had a close to significant impact on the
difference score between the cognitive and the exposure
block, F(1,52) = 3.96, p = 0.052, ph
2 = 0.07. Women
had higher difference scores and thus more symptoms
relieve than men. Importantly, additional analyses did
not yield evidence for a sex × COMTval158met geno-
type interaction on the difference score between the
cognitive and the exposure block, F(1,56) < 1.
A Mann-Whitney-U test revealed no difference
between the COMTval158met genotype groups for the
HADS depression scale during the course of treatment
using difference scores as described above, p = 0.16.
Discussion
We present first evidence that PD patients with the
COMTval158met met/met genotype may profit less
from exposure-based CBT treatment methods as com-
pared to patients carrying at least one val-allele (val/val
+ val/met). We were thus able to transfere findings of
the association of the COMTval158met polymorphism
from an experimental extinction study [3] obtained
using healthy subjects to a clinical setting. Furthermore,
our finding of (tendentially) more severe symptom
severity in patients with the COMT val-allele (prior to
CBT treatment) is in line with studies showing an asso-
ciation of the COMT val-allele with the diagnosis of PD
in Caucasians [12]. As we observed tendentially more
symptoms of anxiety and anhedonia in val-carriers prior
to CBT but no differences in symptom severity after
10-weeks of CBT, this supports our finding of differen-
tial efficacy of CBT depending on the COMTval158met
polymorphism. Further, we can exclude the possibility
that this differential treatment response may be driven
by the met/met group having tendentially lower anxiety
symptom scores prior to treatment and thus less room
for improvement, as we inclusion of the pre-treatment
symptom scores as a covariate in our additional analysis
did not change our results.
Importantly, including additional covariates (age,
depression, medication status, sex, type of CBT treat-
ment, pre-treatment symptom scores) that may theoreti-
cally have an effect on our outcome measures did not
change our results significantly. Thus, even though the
literature suggests a sex-specific effect of the COMT-
val158met polymorphism in mental disorders [e.g.,
[12,20]], we did not detect evidence for a sex-specific
effect on symptom ratings or efficacy of CBT treatment.
Exposure treatment in CBT which is a gradual expo-
sure to the actual, feared stimulus in the patients mind
and real life situations is the most empirically validated
and active ingredient of CBT for anxiety disorders. This
procedure is based on the theory that the fear response
has been classically conditioned and that subsequently
negatively reinforced avoidance behavior maintains this
fear [21]. Through exposure to the feared stimuli this
vicious circle can be interrupted and extinction occurs
as desensitization to the anxiety-provoking stimuli.
Extinction represents not simply forgetting but an active
learning process resulting in structural and chemical
changes in the brain [22].
It is both of theoretical and clinical interest to identify
biological markers for individualization of both CBT
and pharmacological treatment because a significant
proportion of patients do not respond to either one or
both treatment forms or do not tolerate and complete a
specific treatment.
Currently, there is a lack of studies investigating the
role of genetic variants in the efficacy of CBT in PD,
while some pharmacogenetic studies exist [e.g. [23]].
This gap in the literature probably originates in the his-
torical bias to consider pharmacological treatment as a
“biological” treatment which would have biological cor-
relates of symptoms relief. CBT in turn is historically
considered as a psychosocial intervention without biolo-
gical correlates. However research has clearly shown,
that the changes in affect, behavior and cognition seen
after CBT treatment have biological underpinnings and
are accompanied by significant and disorder specific
changes in brain metabolism [for a review see eg.,
[1,24]].
Despite the paucity of studies in PD, studies concern-
ing other psychiatric disorders are emerging. Very
Lonsdorf et al. BMC Psychiatry 2010, 10:99
http://www.biomedcentral.com/1471-244X/10/99
Page 5 of 9recently, it has been shown in PTSD patients that car-
riers of the 5-HTTLPR s-allele/LG profit less from CBT
as compared to non-carriers in a sample of 45 patients
[25]. This has not yet been investigated in PD patients
and may be an interesting additional or even a con-
founding factor in our results. Thus, 5-HTTLPR/
rs25531 genotype was also analyzed in our material and
the major analyses of this manuscript were also per-
formed with 5-HTTLPR/rs25531 genotype as dependent
variable (see additional files 2 and 3). While the s-allele/
LG-allele of the 5-HTTLPR (both bi- and triallelic) gen-
otype was associated with higher symptom severity prior
to CBT, no association between this genotype (both bi-
and triallelic) and the outcome of CBT was observed.
Importantly, the association of COMTval158met geno-
type remained significant after entering 5-HTTLPR
(both bi- and triallelic) as an additional covariate (p =
0.03). Thus 5-HTTLPR seems not to be associated with
outcome of CBT treatment in PD patients.
Panic attacks are thought to originate from an abnor-
mally sensitive fear network involving the amygdala
[21]. During treatment, the amygdala is thought to be
inhibited either directly by medications such as SSRIs or
indirectly by medial and ventral prefrontal areas exerting
a kind of cognitive control over the amygdala [26]. The
latter process is thought to be mediated by CBT, which
shares a final common result with pharmacotherapy:
namely symptom relief. The COMTval158met poly-
morphism may have a significant impact on this type of
top-down regulation as it is known to affect prefrontal
dopamine levels and prefrontal cortex functioning and
the emotional perseveration, observed as a failure of
extinction or obtaining symptom relieve from exposure-
based CBT in the met/met group, most likely reflects
impaired cognitive control over emotional reactions.
Prior studies investigating the COMTval158met poly-
morphism in PD have mainly focused on case-control
comparisons and results have been mixed. Our finding
of (tendentially) higher symptom severity in val-allele
carriers prior to CBT treatment corroborates several
findings on an association of the val-allele with PD
[10,11]. A recent meta-analysis [12] suggested that in
Caucasians the val-allele m a yb ea s s o c i a t e dw i t hP D ,
while in Asians the met-allele may be the risk allele for
the development of PD. Our data suggest that the
COMT 158val allele may be associated with more severe
symptoms of general anxiety and possibly also depres-
sion in PD patients.
On the other hand in our dataset, patients with the
met/met genotype seem to be overrepresented. It is
known that a deviation from HWE could also reveal
possible genotyping problems. However we used a
Taqman® assay for genotyping which is a very robust
method and all the genotypes were determined in
duplicates. We also run the samples on the same
384-plate as samples from other to date unpublished
studies involving healthy individuals and these popula-
tions did not show a deviation from HWE. As geno-
typing error seems unlikely, patients with the met/met
genotype seem to be overrepresented among our PD
patients. As we do not report data on an additional
healthy control group, we cannot draw any conclusions
about overrepresentation of these individuals. Future
studies using much larger sample sizes as well as ade-
quate control groups should clarify if individuals with
the met/met genotype are overrepresented in patients
with PD and thus may be more prone to the develop-
ment of PD.
Limitations
Limitations of our study include: First, the use of the
HADS can be questioned as it is not a direct measure of
either panic or depression, but rather symptoms of gen-
eral anxiety symptoms (anxiety subscale) and the state
of anhedonia (depression subscale) [15]. However our
findings on the effect of the COMTval158met genotype
on CBT treatment outcome were specific for the anxiety
subscale, indicating that the symptom reduction of gen-
eral anxiety symptoms specifically are associated with
the COMTval158met genotype. Nevertheless, future stu-
dies should make sure to also include panic-specific
symptom dimensions in addition to general anxiety and
depression.
Second, our sample may be biased by a selection on
social class and level of education as access to and will-
ingness to use internet was a prerequisite for inclusion,
thus limiting the generalizability of our findings. On the
other hand, the majority 92%) of Swedish citizens has
regular access to the Internet http://www.internetworld-
stats.com.
Third, it needs to be mentioned that almost half of the
patients were medicated and it is possible that there
may be an overrepresentation of patients who did not
respond well to the pharmacological treatment. We can-
not finally exclude the possibility that medication status
may affect treatment outcome, maybe even in a geno-
type dependent manner or that medication may have
additional effects during the observational period even
after 8 weeks of stable medication. However an effect of
co-medication is rather unlikely, given that we do not
find an effect of medication status on the symptomatic
profile at any point of time. No differences in medica-
tion status between the genotype groups and treatment
arm groups were observed either. Furthermore and
importantly, entering medication status as a covariate in
our primary analyses still yielded a significant effect of
COMTval158met genotype on outcome of exposure
based CBT treatment.
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ential efficacy of one of the two treatment modes (iCBT
vs. gCBT) depending on the COMTval158 genotype.
However the frequency of the COMTval158met geno-
type groups did not differ between the two treatment
arms (see Table 1) and entering type of treatment as an
additional covariate in our analysis did not change our
results significantly. Additionally and importantly, it has
been demonstrated convincingly that iCBT and gCBT
do not differ in their efficacy in the treatment of PD
[27-29,13]. Nevertheless future studies using larger sam-
ple sizes, only non-medicated patients and more homo-
geneous treatment protocols are warranted to follow-up
on our findings.
Fifth, given that we observed pre-existing differences
with respect to the frequency of mild co-morbid depres-
sion this may have introduced a bias in our results. This
difference when it comes to the frequency of co-morbid
depression may in fact be meaningful in itself and in
this case, controlling statistically for this differences
would be inappropriate. However and importantly, we
demonstrated in our additional analyses that our pri-
mary results do not differ when including or not includ-
ing this variable as a covariate in the analyses.
Sixth, due to missing HADS measurements after each
module, we were not able to perform a repeated mea-
surement ANOVA and merged modules with similar
content to blocks (cognitive vs. exposure block). The
reason for the missing data, in particular in later mod-
ules, is that the number of modules patients went
though during the ten-week treatment period differed
between patients. Importantly, the number of modules
finished did not differ between the COMTval158met
genotype groups (see Table 1). Thus it is highly unlikely
that our results are due to a selective drop out of
patients moving forward slowly.
Seventh, we cannot exclude the possibility that the dif-
ferential effect during the exposure block seen for the
COMTval158met genotype groups may in fact represent
an effect of the cognitive modules or treatment generally
with a delayed onset or a more consolidated fear mem-
ory rather than an effect of extinction. Treatment stu-
dies have however shown that for CBT for phobic
disorders, behavioral interventions (relying heavily on
the principle of extinction) predominate over cognitive
ones [for a review see e.g., [24]]. In light of this and in
particular given the theoretical basis of our hypothesis
we consider it anyhow justified to interpret our results
suggestive of a differential effect of exposure based
treatment methods.
Interestingly, treatment outcome to different types of
treatments has also been associated to the COMT-
val158met polymorphism in various patient populations.
In depressive patients the val/val genotype has been
associated with better response to electroconvulsive
treatment [ECT, [30,31]][32] and pharmacological treat-
ment [33,34]. However, it needs to be mentioned that
the literature is not entirely conclusive [35]. In addition,
treatment resistant schizophrenics with the met/met
genotype required higher doses of antipsychotic medica-
tion to achieve a significant reduction in psychotic
symptoms [36]. Thus, patients with the met/met geno-
t y p em a yb eg e n e r a l l yl e s sr e s p o n s i v et oa n yf o r mo f
treatment as compared to their val/val counterparts and
their brain may be less plastic to changes induced by
interventions.
Conclusions
Despite of these limitations, this is to our knowledge the
first study in which the response to CBT has been asso-
ciated with a genetic marker in PD. The field of phar-
macogenetics has in principle been limited to the study
of drugs while CBT has only been considered in one
very recent report in PTSD [37]. Additionally, PD has
been fairly neglected so far in pharmaco/psychotherapy-
genetic studies. The clinical implication of our finding is
that the outcome of psychological treatments may be
gated by the patient’s genetic profile. If the patient’s
genetic profile can be related to the likelihood to profit
from a specific form of treatment, this would imply that
treatment could be optimized according to this profile.
While the development of drugs that may target a small
population is quite costly, personalized administration of
CBT would not be likewise cost-intensive. It may be
possible that patients with the met/met genotype would
need a more intense or prolonged exposure treatment
in order to achieve the same symptom relief as patients
that carry a COMT val -allele. Alternatively they may
profit from additional treatment (e.g. pharmacotherapy).
In fact, cognitive enhancers such as d-cycloserine have
been found to boost the effect of exposure treatment
[38]. It is possible that this effect may be gated by the
patients genetic make-up. Similar to drug dosage recom-
mendations, the intensity or dosage of CBT may take
the genetic profile of the patient into account.
Psychotherapy can be regarded as a form of learning
from the environment, and the learning process occur-
ring during psychotherapy most likely produces altera-
tions of gene expression and thereby strength in
synaptic connections in the brain [39]. That we find a
common genetic polymorphism (COMTval158met) to
be differentially associated with the efficacy of exposure-
based treatment in panic patients may suggest an inter-
esting new possible venue of gene × environment inter-
action, even though the association study approach that
we used does not allow to conclude a causal link and
future replication studies using larger samples (300-500
individuals) are however warranted.
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